Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 11/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 11/20 | 0.72 |
| ▸ | MAPT | P10636 | 7/20 | 0.72 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913813 | 0.80 | MEN1 (1.00) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL1702691 | 0.80 | MEN1 (0.65) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL18796167 | 0.80 | ALDH1A1 (0.59) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| Methane SCHEMBL27598399 | 0.79 | MEN1 (0.97) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL29642602 | 0.78 | ALDH1A1 (1.00) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL2230388 | 0.78 | ALDH1A1 (1.00) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| Methane SCHEMBL28038323 | 0.77 | ALDH1A1 (0.96) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL28747081 | 0.77 | ALDH1A1 (0.96) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL1703113 | 0.76 | CYP1A2 (0.57) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL20796131 | 0.76 | MEN1 (0.74) | MEN1KMT2AMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440546-B1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | ABIVAX (FR) | 2022-12-28 | — | — | EP | claimed |
| EP-2440547-B1 | New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects | ABIVAX (FR) | 2022-11-30 | — | — | EP | claimed |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | ABIVAX (FR) | 2020-06-16 | — | — | US | claimed |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2018-11-29 | — | — | US | claimed |
| US-9827237-B2 | Compounds useful for treating diseases caused by retroviruses | ABIVAX (FR) | 2017-11-28 | — | — | US | claimed |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-06-02 | — | — | US | claimed |
| EP-3016656-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | ABIVAX (FR) | 2016-05-11 | — | — | EP | claimed |
| US-9145367-B2 | Compounds useful for treating AIDS | ABIVAX (FR) | 2015-09-29 | — | — | US | claimed |
| US-9108919-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2015-08-18 | — | — | US | claimed |
| WO-2015001518-A1 | BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | SPLICOS (FR) | 2015-01-08 | — | — | WO | claimed |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2014-03-20 | — | — | US | claimed |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | SOCIETE SPLICOS (FR) | 2012-12-27 | — | — | US | claimed |
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIETE SPLICOS (FR) | 2012-11-08 | — | — | US | claimed |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIETE SPLICOS (FR) | 2012-11-01 | — | — | US | claimed |
| EP-2440547-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | Société Splicos (FR) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143169-A2 | COMPOUNDS USEFUL FOR TREATING AIDS | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| WO-2010143168-A2 | COMPOUNDS USEFUL FOR TREATING CANCER | SOCIÉTÉ SPLICOS (FR) | 2010-12-16 | — | — | WO | claimed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | claimed |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | ABIVAX (FR) | 2024-10-17 | — | — | US | disclosed |
| EP-2261214-A1 | Compounds useful to treat premature aging and in particular progeria | Splicos Sas (FR) | 2010-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283265-A1 | COMPOUNDS USEFUL FOR TREATING AIDS | CBR1, CNR1, CBR3 | MEN1 3647/4885KMT2A 2336/4885MAPT 4329/4885 |
| US-10683284-B2 | Compounds for preventing, inhibiting, or treating cancer, aids and/or premature aging | RCOR1, NR3C1, NR5A1 | MEN1 2482/4885KMT2A 1667/4885MAPT 3932/4885 |
| US-20120277230-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | CBR1, CBR3, NCOR1 | MEN1 1925/4885KMT2A 1666/4885MAPT 4736/4885 |
| US-20240343716-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | MEN1 2482/4885KMT2A 1667/4885MAPT 3932/4885 |
| US-20120329796-A1 | COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA | NR2C2, NCOR2, NR4A2 | MEN1 3042/4885KMT2A 2740/4885MAPT 4162/4885 |
| US-20180339981-A1 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | RCOR1, NR3C1, NR5A1 | MEN1 2482/4885KMT2A 1667/4885MAPT 3932/4885 |
| US-20160151348-A1 | COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES | RCOR1, CBR1, RCOR3 | MEN1 2704/4885KMT2A 1742/4885MAPT 3658/4885 |
| US-20140080831-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | NR1H4, NR1H3, NCOR1 | MEN1 1720/4885KMT2A 1903/4885MAPT 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.